Sponsored Content
Valneva
Austro-French Vaccine Company Valneva's Covid-19 Jab under EU Review
The EU's medicines agency EMA launched an accelerated review of a Covid-19 vaccine by Austro-French biotech firm Valneva. Recently the European Commission agreed to buy as many as 60 million doses of its Covid-19 vaccine. The deal would allow EU member states to purchase almost 27 million doses from Valneva in 2022, and an additional 33 million in 2023.
December 2, 2021
Valneva Completes EUR 45 Million Capital Increase
The listed biotechnology company Valneva SE announces the completion of its capital increase with shareholders preferential subscription rights launched on January 12th, 2015. Valneva estimates net proceeds of EUR 42 millions from 18.2 million offered new shares. The new ordinary shares will be traded on Euronext and on the Prime Market segment of the Vienna Stock Exchange. The financing will mainly be used for the acquisition of Crucell Sweden AB and all assets, licenses and privileges related to Dukoral.
February 4, 2015
Fast News Search
